Provided by Tiger Trade Technology Pte. Ltd.

Tango Therapeutics Inc.

22.84
-0.5000-2.14%
Post-market: 22.840.0034+0.01%16:20 EDT
Volume:1.85M
Turnover:42.20M
Market Cap:3.86B
PE:-27.19
High:23.50
Open:23.28
Low:22.61
Close:23.34
52wk High:34.39
52wk Low:6.25
Shares:169.00M
Float Shares:142.96M
Volume Ratio:0.80
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8400
EPS(LYR):-0.8746
ROE:-21.34%
ROA:-12.99%
PB:3.77
PE(LYR):-26.12

Loading ...

Top Midday Gainers

MT Newswires Live
·
Jun 09

Catanzaro Raises TNGX Price Target to $36, Reiterates Buy on Promising Vopimetostat/Daraxonrasib Data in Pancreatic Cancer

TIPRANKS
·
Jun 09

BUZZ-U.S. STOCKS ON THE MOVE -Tango Therapeutics, Intel, Ciena

Reuters
·
Jun 09

Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment -- Barrons.com

Dow Jones
·
Jun 09

Top Midday Stories: US Weighs Financial Stakes in AI Firms; Google, Nvidia Turn to Intel as TSMC Struggles With Demand

MT Newswires Live
·
Jun 08

Tango Therapeutics rises 32.1%

TIPRANKS
·
Jun 08

RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position

TIPRANKS
·
Jun 08

Sector Update: Health Care

MT Newswires Live
·
Jun 08

Tango Therapeutics Shares Rise 45% Premarket After Co's Pancreatic Cancer Drug Combo Shows Promise in Study

THOMSON REUTERS
·
Jun 08

Tango Therapeutics' pancreatic cancer drug combo shows promise in study

Reuters
·
Jun 08

Tango Therapeutics Says Initial Results From Phase 1/2 Trial of Pancreatic Cancer Drug Candidate Showed Improvement in Survival Rate; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 08

Tango Therapeutics announces data from study of vopimetostat, daraxonrasib

TIPRANKS
·
Jun 08

Tango Therapeutics - Vopimetostat Plus Daraxonrasib Generally Well Tolerated With No New Safety Signals

THOMSON REUTERS
·
Jun 08

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

THOMSON REUTERS
·
Jun 08

Tango Therapeutics - to Advance Vopimetostat Plus Daraxonrasib Into Phase 3 for Mtap-Deleted Pancreatic Cancer

THOMSON REUTERS
·
Jun 08

A Look At Tango Therapeutics (TNGX) Valuation As Optimism Builds Around Upcoming Pancreatic Cancer Data

Simply Wall St.
·
Jun 07

Tango Therapeutics grants new hire 170,000-share stock option at $23.1, awards 40,000 RSUs

Reuters
·
Jun 05

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 05

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

Tango Therapeutics shareholders elected two Class II directors at annual meeting

Reuters
·
Jun 05